Negative Cash Flow & Ongoing LossesPersistent negative operating and free cash flows demonstrate structural unprofitability despite revenue gains. Continued cash burn limits flexibility to invest in sales, approvals, or supply chain, raising the probability of future financing, dilution, or painful cost cuts that could impede long-term growth.
Decline In Legacy ContraPest SalesA ~31% YoY drop in ContraPest revenues highlights product-mix risk and erosion of a legacy revenue stream. If growth from Evolve or other channels slows, the company may face net revenue pressure, reducing predictability and making it harder to sustain fixed costs and fund expansion without offsetting gains.
Executive Leadership Transition RiskAnnouncement of the CEO’s pending retirement and appointment of an interim executive chair creates strategic and execution uncertainty during a scaling phase. Leadership turnover can delay critical decisions, disrupt partner and municipal relationships, and increase execution risk for commercialization and international approvals over months.